Related Experiment Video

Updated: Jul 16, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole

T Saussele1, O Burk, J K Blievernicht

  • 1Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Clinical Pharmacology and Therapeutics
|March 9, 2007
PubMed

Insights

Metamizole, a common pain reliever, significantly increases the expression of drug-metabolizing enzymes CYP2B6 and CYP3A4 in the liver. This induction may affect how other medications are processed, especially during long-term use.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Hepatology

Background:

  • Metamizole is a widely used pyrazolone analgesic.
  • Drug-induced changes in liver enzyme expression can lead to significant drug-drug interactions.

Purpose of the Study:

  • To investigate the effects of metamizole on the expression of key drug-metabolizing enzymes in human liver microsomes and hepatocytes.
  • To explore the mechanism underlying metamizole's effects on enzyme expression.

Main Methods:

  • Analysis of liver microsomes from patients treated with metamizole.
  • Incubation of human primary hepatocytes with metamizole and its derivatives.
  • Measurement of enzyme activity (bupropion hydroxylase) and gene/protein expression (CYP2B6, CYP3A4).
  • Reporter gene assays to assess interaction with nuclear receptors (PXR, CAR).

Main Results:

  • Metamizole treatment led to significantly higher expression of CYP2B6 (3.8-fold) and CYP3A4 (2.8-fold) in patient liver microsomes.
  • In hepatocytes, metamizole induced CYP2B6 and CYP3A4 mRNA and protein in a time- and concentration-dependent manner.
  • Metamizole did not directly activate PXR or CAR, suggesting an indirect induction mechanism.

Conclusions:

  • Metamizole induces the expression of CYP2B6 and CYP3A4, potentially altering the metabolism of co-administered drugs.
  • The induction mechanism appears to be phenobarbital-like, not involving direct ligand binding to PXR or CAR.
  • Further research is warranted to fully understand metamizole's drug-interaction potential, particularly in patients undergoing long-term therapy.

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...